Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated March 04, 2021.

Dr Reddy's launches stomach, esophagus problems treatment drug in the US

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA).

Dr Reddy's begins process to obtain emergency use authorisation for Sputnik V

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia, the statement said.

Dr Reddy's launches Fluphenazine Hydrochloride tablets in US

The product is a therapeutic equivalent generic version of Prolixin tablets approved by the US Food and Drug Administration (USFDA).

Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research report dated January 31, 2021.

Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 29, 2021.

Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research report dated January 30, 2021.

Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dated January 30, 2021.

Dr Reddys Labs Standalone December 2020 Net Sales at Rs 3,408.20 crore, up 11.96% Y-o-Y

Dr Reddy's Labs Q3 profit at Rs 20 crore, revenue rises 12% YoY

The company said the Q3FY21 PAT was impacted primarily due to the non-recognition of deferred tax assets on impairment.

Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, led by the launch of Kuvan.

Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 12, 2021.

Mumbai airport to handle over half of SII's Covishield vaccine

The Indian government will launch the vaccination drive from January 16, and the transportation of the vaccines may begun from January 11, to ensure a steady supply chain.

Serum Institute gets ahead in COVID-19 vaccine, but opportunity still exists for others

Serum Institute alone cannot inoculate the entire population at one go. This leaves enough space for competitor vaccines, provided they succeed in clinical trials

Russia will jointly produce Sputnik V vaccine for COVID-19 with India: Russian envoy Nikolay Kudashev

The vaccine was developed by the Gamaleya Research Institute while the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, is investing in the production and promotion of the vaccine abroad.

Dr Reddy’s Laboratories shares gain as firm commences clinical trials for Sputnik V vaccine

The clinical trials are being conducted by JSS Medical Research who are the clinical research partner.

Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 6000 in its research report dated October 29, 2020.

Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey

KR Choksey recommended accumulate rating on Dr. Reddy’s laboratories with a target price of Rs 5418 in its research report dated October 30, 2020.

Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market

Dolat Capital Market recommended accumulate rating on Dr Reddy's Laboratories with a target price of Rs 5414 in its research report dated October 28, 2020.

Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5964 in its research report dated October 29, 2020.

Dr Reddy's Labs shares jump after Credit Suisse maintains outperform rating, expects earnings momentum to continue

Credit Suisse is of the view that Q2 was better than expected with strength driven by US sales. Earnings momentum should continue with more limited competition launches.

Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y

Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y

Dr Reddy's plans to complete phase 3 trial of Sputnik V COVID vaccine by March end

CEO Erez Israeli said the company would begin phase II trials in the next few days